Takeda fiscal 2014 results in line with guidance
Japan’s largest drugmaker, Takeda Pharmaceutical (TYO: 4502) has posted fiscal 2014 (year ended March 31, 29015) financial results in line with guidance. With underlying revenue growth of 2.8% to 1,691.7 billion yen ($14.09 billion) and underlying core earnings -2.1% to 314.2 billion yen, Takeda met its operational guidance for FY2014.
Reported revenue grew by 5.1% to 1,777.8 billion yen. The booking of a $2.7 billion provision to cover the Actos (pioglitazone) settlement and estimated costs associated with remaining cases and other related litigations, along with other one-time exceptional items, impacted operating profit (a loss of 129.3 billion yen), net profit (-145.8 billion yen) and earnings per share (-185 yen).
Back to profitable growth from FY2015
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze